AGL — Agilon Health, Inc.

Summary of AGL Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Membership: Ended Q4 2025 with 511,000 Medicare Advantage members and 114,000 ACO REACH members.
• Revenue: Q4 revenue was $1.57 billion; total revenue for 2025 was $5.93 billion.
• Medical Margin: Q4 medical margin was negative $74 million; full-year margin was negative $57 million.
• Adjusted EBITDA: Q4 adjusted EBITDA was negative $142 million; full-year adjusted EBITDA was negative $296 million.
• Cost Trends: Medical cost trend for Q4 was recorded at 7.4%, with a full-year trend of approximately 6.5%.

2. Strategic Updates and Business Highlights

• Focused on operational discipline and transformation towards a sustainable performance model.
• Emphasized partnerships with community-based physicians, enhancing clinical pathways, and improving quality programs.
• Advanced initiatives in data visibility and actuarial capabilities to better manage risk and improve outcomes.
• Executed $35 million in operating cost reductions, exceeding previous targets.
• Continued development of clinical pathways for chronic conditions, with heart failure programs adopted by over 90% of the network.

3. Forward Guidance and Outlook

• 2026 Projections:
  • Expected revenue between $5.41 billion and $5.58 billion.
  • Anticipated medical margin of $300 million to $350 million.
  • Adjusted EBITDA expected to range from negative $15 million to breakeven.
  • Projected membership to be between 525,000 and 540,000, including 430,000 in Medicare Advantage.
• Anticipated elevated cost trends of approximately 7.5% for 2026, influenced by ongoing market dynamics and payer behaviors.

4. Bad News, Challenges, or Points of Concern

• Financial performance in 2025 was below expectations, with significant losses in medical margin and adjusted EBITDA.
• Concerns regarding the adequacy of CMS's advanced rate notice, which may not reflect the rising costs and utilization trends.
• Membership reduction due to exiting unprofitable payer contracts, leading to a decrease in total members.
• Elevated medical cost trends, particularly in Q3, driven by increased inpatient stays and large claims.

5. Notable Q&A Insights

• Management acknowledged the challenges in accurately predicting cost trends, with Q3 experiencing higher-than-expected inpatient costs.
• The company is committed to a disciplined approach in contracting, prioritizing profitability over growth.
• Discussions highlighted the potential impact of the CMS rate notice on future performance, with management expressing hope for adjustments that better reflect industry realities.
• The ACO REACH program was noted as a positive contributor, with expectations for continued improvement in quality performance and incentives.

Overall, while AGL is navigating significant challenges, particularly in financial performance and cost management, the company is focused on strategic initiatives aimed at long-term sustainability and profitability.